Lipocine Inc. (NASDAQ:LPCN) does about 3.67M shares in volume on a normal day but saw 11752710 shares change hands in Friday trading. The company now has a market cap of 108.40M USD and an enterprise value of about $96.41M. Its current market price is $1.65, marking a decrease of 0.00% compared to the previous close of $1.65. The 52 week high reached by this stock is $3.45 whilst the lowest price level in 52 weeks is $0.30. The script in recent trading has seen the stock touch a high of $1.76 and a low of $1.55.

Lipocine Inc. (LPCN) has a 20-day trading average at $1.9218 and the current price is -52.17% off the 52-week high compared with 448.17% distance from its 52-week low. The 50-day simple moving average of the closing price is $1.5623 and its 200-day simple moving average is $0.7948. If we look at the stock’s price movements over the week, volatility stands at 17.72%, which decreases to 11.36% over 1 month. It is also key to look at other market indicators of price movement for the stock, where we see that the relative strength index (RSI) is at 46.13 to suggest the stock is neutral.

2 analysts observing the Lipocine Inc. (LPCN) stock have set the 12-month price targets for the company’s shares at between $3.00 and $3.00. The median price target is 45.0% away from the current levels at $3.00.

FactSet Research has provided data showing that 2 brokerages have issued ratings for the stock. 0 analysts have rated it as a sell, while 0 advise that it is a overweight. 1 analysts have rated it as a buy and 1 have advised that investors hold their positions. The consensus recommendation rating is Overweight and Wall Street’s advice is for investors to Moderate Buy the stock.

The company shares received a number of brokerage firm price updates over the past month, with the latest being on January 12, 2018 when H.C. Wainwright reiterated the stock to “Buy” and issued a price target of between $10 and $3. Canaccord Genuity downgraded the stock to “Hold” from Buy on January 11, 2018 at a price target of $11-$2. H.C. Wainwright resumed its price target at $10.

The current price level is -13.89%, 6.61%, and 108.72% away from its SMA20, SMA50, and SMA200 respectively, with the LPCN price moving below the 50-day SMA on August 28. Lipocine Inc. (LPCN) stock is down -14.95% over the week and 9.27% over the past month. Its price is 328.68% year-to-date and -40.00% over the past year.

The stock last released its quarterly earnings report for quarter ended 6/29/2020, with the company’s earnings per share (EPS) of -$0.13 below consensus estimates by -$0.06. The company’s next earnings report is expected on 11/04/2020, with forecasts estimating quarterly EPS at -$0.06 and -$0.35 for whole year. LPCN’s earnings per share are forecast to grow by 30.00% this year and 97.10% over next year.

Its 12-month price target is $3.00. Of course, the average price target is just what the average analysts believe a stock will be worth in the next 52 weeks, and is only one metric. There are analysts with lower targets than the average, including one bearish Wall Street research firm advocating investors to wait for the price to pull back to $3.00, given the recent momentum. And then, on the bullish side of things, one analyst is expecting the stock to peak at $3.00.

Outstanding shares total 65.69M with insiders holding 3.68% of the shares and institutional holders owning 17.76% of the company’s common stock. The company has a return on investment of -96.30% and return on equity of -221.30%. The beta has a value of 0.60. Price to book ratio is 6.35 and price to sales ratio is 542.02.

According to a U.S. Securities and Exchange Commission filing, Vanguard Total Stock Market Index has reduced its position in Lipocine Inc. (LPCN) to 618,404 shares, mirroring a recent drop by 0.00%. Vanguard Total Stock Market Index dumped 0.0 shares of Lipocine Inc. common stock bringing its total worth to about $0.95 million at the end of recent close, SEC documents show. Vanguard Total Stock Market Index isn’t the only investment manager who changed stakes and is followed by Vanguard Extended Market Index Fu, which sold off 0.0 shares to end up with 448,810 shares worth $0.69 million.